(365) Durable efficacy and robust CD4+ T-cell count improvement observed across age, race, sex, and geographic subgroups of heavily treatment-experienced people with multidrug-resistant HIV-1 after 240 weeks of fostemsavir treatment

Regional Medical Lead & US DEI Medical Engagement Lead
ViiV Healthcare
Durham, North Carolina, United States

Chief of Division of Infectious Diseases
Icahn School of Medicine at Mount Sinai
New York, New York, United States

Pr. Jean-michel Molina
UNiversity of Paris CIte
Paris, Ile-de-France, France

Medical Director
Helios Salud
Capital Federal, Argentina

Stanford University
Stanford, California, United States

Mexico Centre for Clinical Research
Mexico City, Estado de México, Mexico

Maxwell Centre
Durban, KwaZulu-Natal, South Africa

Quest Clinical Research
San Francisco, California, United States

Hôpital Tenon, Assistance Publique-Hôpitaux de Paris
Paris, Ile-de-France, France

GSK
Collegeville, Pennsylvania, United States

ViiV Healthcare, Brentford, UK
Brentford, England, United Kingdom

Global Medical Lead
ViiV Healthcare, Brentford, UK
Brentford, England, United Kingdom

Medical Director
ViiV Healthcare
Durham, NC, United States

ViiV Healthcare
Research Triangle Park, North Carolina, United States

ViiV Healthcare
Branford, Connecticut, United States